Open in interactive viewer → charts, metric popovers & call review

Elite Pharma Had a Bidder. It Said No, Then Rallied 56%.

The board shelved a takeout it had spent a year campaigning for, flipped its priorities to a NASDAQ uplist, and pinned the whole equity story on 2027 filings
ELTP · Earnings Call · 2026-11-13

The $40 million that isn't the same $40 million

Elite posted $40.1 million of revenue for the September quarter against $36.3 million a year earlier — a 10% gain. The CFO, Carter Ward, wants you to read that number differently than last time: “our top line is back to the $40 million level, but it's a different $40 million” — Carter Ward, Chief Financial Officer · 2026-11-13. The difference is composition. The $40 million quarter of June 2025 was essentially a Lisdex market artifact — generic Vyvanse at pre-correction prices. That correction has run its course; what replaced it is breadth: the ADHD product family (mixed amphetamine salts IR and ER) plus the opioid addiction and pain lines. Concentration risk is genuinely lower, which is worth something. But the arithmetic underneath the narrative is grimmer. This is the slowest growth rate in the recent record: the June 2026 quarter came in at $41 million, up 27% year over year, and this quarter grew 10%. Gross margin, 40% versus 39% a year ago, got there by falling from 54% — the price erosion from new Lisdex competitors is now visible in the margin line rather than the revenue line. And management is candid that the biggest product is constrained by the DEA, not by demand: “Quota is an issue for Lisdex. We are not getting it as fast as we would like to... it's like almost hand to mouth.” — Nasrat Hakim, Chairman and Chief Executive Officer · 2026-11-13 That is a structural quota-and-plant capacity ceiling on the one product that has carried the P&L.

The buyer showed up. The board said not yet.

The most consequential thing on this call had nothing to do with the third quarter. Nasrat Hakim disclosed that roughly three weeks ago his bankers conveyed a verbal offer from one of the parties that had already visited and diligenced the company.

The Board discussed the proposal and voted to pass on that opportunity. The Board decided to shelf the negotiations for now... even though they gave us what we wanted, the price changed so drastically that, that's not really what we want anymore.

Nasrat Hakim, Chairman and Chief Executive Officer · 2026-11-13
Read that twice. The company set a premium hurdle, the bidder cleared the hurdle, and the board declined anyway — citing a share price that had moved lower since the ask was framed, not the offer itself. The interested party is being invited back in 2027 after a few bioequivalence studies, an approvable letter on the anticoagulant, and some facility progress. This is a straight reversal of stated priority, and the prior calls show it. In July 2025 Hakim was unambiguous: “Our top priority is merger and acquisition, a buyout. If that does not work, then NASDAQ is an option.” — Nasrat Hakim, Chairman and Chief Executive Officer · 2025-07-01 He even gave a clock on the process: “We will decide if we will enact Phase 2 within the coming 3 to 4 months.” — Nasrat Hakim, Chairman and Chief Executive Officer · 2025-07-01 Seventeen months later, Phase 2 produced a bid and was shelved. The stated hierarchy has inverted: NASDAQ — with its uplist to NASDAQ target of March 2027 and NASDAQ listing application in calendar Q1 — is now the plan, and M&A is the option. The market is not obviously aggrieved. The tape shows a stock that fell 31% over seventeen weeks to mid-November, then ripped 56% in five sessions — with a 52% nine-day surge in the trailing 90-day window and only a 7.3% drawdown from the July 16 peak of $0.40. A rejection of a takeout offer is usually a sell signal for a $345 million microcap. Here it was a rally. Either investors are pricing the "2027 re-rating" story or they simply read the disclosure as leverage. That is a genuine disagreement worth watching.

Five pillars, one filing date

Hakim's presentation reframes the equity as a pipeline story rather than a generic-commodity story. The pillars: the ADHD franchise; anticoagulants, including an undisclosed ANDA with a March 2027 GDUFA date and an expected 2028 launch amid hopes for approvable status; type 2 diabetic products with a first bioequivalence study in the first half of 2027; pain and opioid addiction, where generic OxyContin ER still hinges on FDA; and CNS, where a successful study supports an anticonvulsant ANDA filing in Q1 2027 against an IQVIA-reported $840 million brand. The company's own summary is a slogan: "2027 is going to be the year of R&D and 2028 is the year of the second growth." The physical plant is being built to match: management counts 85,000 square feet of GMP space today across the buildings it owns and the one across the street, rising to 130,000 once the rest of that building is leased — a lease, notably, not yet signed, and first commercial batches from the expansion are floated at 2028. Skepticism is warranted on timing. Hakim has form on near-term FDA optimism; in November 2024 he told listeners about a pending approval, “there is no reason why they shouldn't approve us next week” — A - Nasrat Hakim, Chairman and CEO · 2024-11-16 — and the current pipeline is now framed almost entirely in 2027 and 2028 dates. Note also what the R&D pipeline costs today: R&D expense was $2 million against $41 million of revenue in the June quarter — roughly a nickel of every dollar, and itself down 20% year over year before the step-up management now promises.

Internal controls, warrants, and the balance sheet that does the talking

The new top keyword this quarter, by the company's own extraction, is internal controls — a topic that surfaces only when a listing or an audit is coming. Sarbanes documentation and testing must be in place before the fiscal-2028 independent audit, which means April 2027. “It's a high-priority project. I want to have this in place when we're on the NASDAQ.” — Carter Ward, Chief Financial Officer · 2026-11-13 It is a mundane answer to an investor question and, simultaneously, the real gating item on the whole re-rating story. Financially, the balance sheet is the strongest argument management has. Cash rose to $35 million from $30 million at fiscal year-end; working capital is $103 million; liabilities excluding non-cash derivatives fell to $14.5 million from $22.1 million. Liabilities to assets sit at 28.5%, down 16 percentage points year over year. The warrant overhang — 79 million shares, roughly $12 million if cash-exercised, expiring April 2027 — is the wildcard, and its mark-to-market runs through the P&L: effective SG&A jumped 278% year over year in the June quarter, which is why the headline net-income numbers whipsaw while cash keeps building. One blemish deserves a flag rather than a paragraph: receivables ran at 146.5% of quarterly revenue, up 55 points year over year. The CFO's explanation is coherent — inventory and receivables build ahead of sales, and the swing cost about $11 million of operating cash flow in the quarter — but receivables at one-and-a-half quarters of revenue is a long leash, even for a company selling through wholesalers. The honest summary: Elite's operations are stabilised, its margin structure is normalising downward, its board just refused a deal it had publicly campaigned for, and the entire forward case now rests on 2027 filings and a NASDAQ ticker. The balance sheet buys them the time. Whether the market should pay for it before the lease is signed is the open question.